Inhaled Corticosteroids: Not Just for Asthma, but for COVID-19?

Overview

Journal Lancet Respir Med

Publisher Elsevier

Specialty Pulmonary Medicine

Date 2022 Apr 10

PMID 35397799

Authors

Felicity Liew

Peter J M Openshaw

Affiliations

Soon will be listed here.

Citing Articles

Bioinformatic analysis and preliminary validation of potential therapeutic targets for COVID-19 infection in asthma patients.

Li Y, Liu Y, Duo M, Wu R, Jiang T, Li P Cell Commun Signal. 2022; 20(1):201.

PMID: 36575422 PMC: 9793391. DOI: 10.1186/s12964-022-01010-2.

Inhaled corticosteroids for the treatment of COVID-19.

Bafadhel M, Faner R, Taille C, Russell R, Welte T, Barnes P Eur Respir Rev. 2022; 31(166).

PMID: 36450371 PMC: 9724831. DOI: 10.1183/16000617.0099-2022.

Clinical benefits of inhaled ciclesonide for hospitalized patients with COVID-19 infection: a retrospective study.

Kuo K, Chen C, Wang C, Wu J, Chung H, Chen Y BMC Pulm Med. 2022; 22(1):368.

PMID: 36171597 PMC: 9517967. DOI: 10.1186/s12890-022-02168-8.

References

Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(8):693-704. PMC: 7383595. DOI: 10.1056/NEJMoa2021436. View

Yu L, Bafadhel M, Dorward J, Hayward G, Saville B, Gbinigie O . Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet. 2021; 398(10303):843-855. PMC: 8354567. DOI: 10.1016/S0140-6736(21)01744-X. View

Schultze A, Walker A, Mackenna B, Morton C, Bhaskaran K, Brown J . Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform. Lancet Respir Med. 2020; 8(11):1106-1120. PMC: 7515601. DOI: 10.1016/S2213-2600(20)30415-X. View

Corti D, Purcell L, Snell G, Veesler D . Tackling COVID-19 with neutralizing monoclonal antibodies. Cell. 2021; 184(12):3086-3108. PMC: 8152891. DOI: 10.1016/j.cell.2021.05.005. View

Ramakrishnan S, Nicolau Jr D, Langford B, Mahdi M, Jeffers H, Mwasuku C . Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med. 2021; 9(7):763-772. PMC: 8040526. DOI: 10.1016/S2213-2600(21)00160-0. View

Bloom C, Drake T, Docherty A, Lipworth B, Johnston S, Nguyen-Van-Tam J . Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. Lancet Respir Med. 2021; 9(7):699-711. PMC: 8241313. DOI: 10.1016/S2213-2600(21)00013-8. View

Habibi M, Thwaites R, Chang M, Jozwik A, Paras A, Kirsebom F . Neutrophilic inflammation in the respiratory mucosa predisposes to RSV infection. Science. 2020; 370(6513). PMC: 7613218. DOI: 10.1126/science.aba9301. View

Fischer 2nd W, Eron Jr J, Holman W, Cohen M, Fang L, Szewczyk L . A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. Sci Transl Med. 2021; 14(628):eabl7430. PMC: 10763622. DOI: 10.1126/scitranslmed.abl7430. View

Baker J, Mahdi M, Nicolau Jr D, Ramakrishnan S, Barnes P, Simpson J . Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis. Lancet Respir Med. 2022; 10(6):545-556. PMC: 8989397. DOI: 10.1016/S2213-2600(22)00002-9. View

10.

Nguyen-Van-Tam J, Openshaw P, Hashim A, Gadd E, Lim W, Semple M . Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza: United Kingdom first wave (May-September 2009). Thorax. 2010; 65(7):645-51. PMC: 2921287. DOI: 10.1136/thx.2010.135210. View